Healthcare entity

SomaLogic

Company

Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Evolent, the most common co-covered peer. At 5, the average consequence score sits below the same-window beat average of 6.

Last mentioned: Feb 24, 2026

Entity pulse

Recent coverage · SomaLogic

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about SomaLogic

Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Evolent, the most common co-covered peer. At 5, the average consequence score sits below the same-window beat average of 6. Each story carries 2 original sources on average, compared with 2.4 for the broader beat in this window. We currently track 1 Healthcare story that mention SomaLogic, all published on February 24, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering SomaLogic. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Earnings Release

    Both EVH and LAB report full-year 2025 financial results to the market.

  2. Asset Realignment

    Standard BioTools completes a significant acquisition/disposition of assets per SEC filings.

  3. Operational Update

    Standard BioTools provides preliminary 2025 performance data and strategic outlook.

  4. SomaLogic Merger

    Standard BioTools completes merger with SomaLogic to expand proteomics capabilities.

Stories mentioning SomaLogic 1

Market Trends Neutral

Evolent and Standard BioTools Q4 Results Signal Strategic Pivot to Profitability

Evolent and Standard BioTools reported Q4 and full-year 2025 financial results, highlighting a sector-wide shift toward operational efficiency and consolidation. While Evolent scales its specialty care management platform, Standard BioTools is navigating the final stages of its SomaLogic integration amidst a complex life sciences market.

2 sources

Source: prnewswire.com · manilatimes.net

SomaLogic is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.